Introduction Economic evaluations are becoming increasingly important due to limitations in
economic resources, the expense of many new treatments, the need to allocate health …

Background Strokes attributed to atrial fibrillation (AF) represent a major cause of adult
disability and a great burden to society and healthcare systems. Objectives Our objective …

Background Stroke prevention is the main goal of treating patients with atrial fibrillation (AF).
Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however …

Abstract Background and Objective Evidence indicates that vitamin K antagonists (VKAs)
and oral anticoagulant therapy are under-utilised for stroke prevention in patients with non …

Objectives Several direct oral anticoagulants (DOACs) have been approved by the
European Medicines Agency since 2008. The aim of the present cost-effectiveness-analysis …

Introduction Atrial fibrillation (AF), one of the major risk factors for stroke, imposing a
substantial burden to the Swedish health care system. Apixaban has demonstrated …

Abstract Background and Objectives Three new oral anticoagulants (NOACs) are currently
approved for stroke prevention and systemic embolism in patients with non-valvular atrial …

Background Apixaban was shown to be superior to adjusted-dose warfarin in preventing
stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional …

Aims Warfarin, a vitamin K antagonist (VKA), has been the standard of care for stroke
prevention in patients with atrial fibrillation (AF). Aspirin is recommended for low-risk patients …

Background—Compared with aspirin, apixaban reduces stroke risk in atrial fibrillation (AF)
patients unsuitable for warfarin by 63% but does not increase major bleeding. We sought to …